3138 Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Documenti analoghi

• 3138 Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
  di: Nevin John, et al.
  Pubblicazione: (2024-08-01)
• Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies
  di: Helmut Butzkueven, et al.
  Pubblicazione: (2024-01-01)
• Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
  di: Helmut Butzkueven, et al.
  Pubblicazione: (2020-10-01)
• Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis
  di: Eileen J. McManus, et al.
  Pubblicazione: (2022-01-01)
• Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
  di: ZYGJ van Lierop, et al.
  Pubblicazione: (2021-05-01)